Press Releases May 21, 2026 07:05 AM

Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference

Lifecore Biomedical to engage investors at William Blair 46th Annual Growth Stock Conference

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
LFCR

Lifecore Biomedical, a NASDAQ-listed CDMO specializing in sterile injectable pharmaceutical products, announced its participation in the upcoming William Blair Growth Stock Conference where its CEO and CFO will meet with investors. The event will be held June 2-4, 2026, in Chicago, IL.

Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference
LFCR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lifecore Biomedical is a fully integrated CDMO with expertise in development and manufacturing of sterile injectable pharmaceuticals including complex formulations.
  • The company manufactures premium injectable-grade hyaluronic acid used across various therapeutic categories.
  • Lifecore's leadership team, including CEO Paul Josephs and CFO Ryan Lake, will participate in investor meetings at the William Blair Growth Stock Conference.
  • The event provides Lifecore an opportunity to enhance investor relations and communicate its strategic growth plans.

CHASKA, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the William Blair 46th Annual Growth Stock Conference. The conference will take place June 2-4, 2026, in Chicago, IL.

Details regarding Lifecore’s participation are as follows:

  • William Blair 46th Annual Growth Stock Conference
    Details: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in investor meetings.
    Conference Dates: June 2-4, 2026
    Location: Loews Chicago Hotel, Chicago, IL

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com

Jennifer Arcure (Media)
917-603-0681
jarcure@vidasp.com

Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
ryan.lake@lifecore.com


Risks

  • Market reception to the company's growth strategies and financial outlook presented at the conference can affect investor sentiment.
  • Competitive pressures in the pharmaceutical CDMO sector, including technological innovations and service differentiation, pose ongoing challenges.
  • Regulatory environment for pharmaceutical manufacturing and complex injectable products introduces uncertainties impacting operations and expansions.

More from Press Releases

Tims China Announces First Quarter 2026 Financial Results Jun 9, 2026 Nathan's Famous, Inc. Reports Year End and Fourth Quarter Results Jun 9, 2026 Parsons Secures a Total of $218 Million on AFRL GARDEM Contracts Jun 9, 2026 Tims China Announces Appointment of Mr. Kwok Wah Cheung as Chief Executive Officer and Issuance of Additional Senior Secured Convertible Notes Jun 9, 2026 Canadian Entrepreneurship Declines, Challenges Build As Companies Fall Behind with Lenders Jun 9, 2026